ImmunoGen seals ADC deal with Jazz

ImmunoGen Inc. (NASDAQ:IMGN) granted Jazz Pharmaceuticals plc (NASDAQ:JAZZ) an exclusive option to develop and commercialize three of ImmunoGen's antibody-drug conjugate (ADC) programs.

Jazz will pay ImmunoGen $75 million up front and $100 million in development funding over seven years to support the three ADC programs...